LEXINGTON, KY--(Marketwired - Feb 19, 2014) - Mapi, the leading expert in Observational Studies, Health Economics and Outcomes Research (HEOR) and Real-World Evidence, announces that Ronald Christensen, M.D., Chief Medical Officer at Mapi and an industry-leading expert in orphan drug development, will make presentations at two major orphan drug conferences. At both events, Dr. Christensen will provide perspectives on the design and implementation of patient registries in orphan drug development, providing specific "lessons learned" to address the inherent challenges of conducting registries in rare disease populations.
Dr. Christensen will speak at the:
- 2nd Orphan Drugs Research & Commercialization Conference at the Hyatt Regency, Mission Bay, San Diego, CA, Friday, February 21. This meeting is a forum for researchers, industry leaders, patient advocacy organizations, and regulatory experts. Dr. Christensen will be the Moderator for Session IV: "Clinical Trials: Lessons Learned & Other Considerations" and participate in a Panel Discussion: "Patient Registries in Orphan Drug Development."
- 4th Annual World Orphan Drug Congress at the Grand Hyatt Hotel, Washington, DC, Friday, April 25. The Congress is the largest, annual global event for stakeholders in the orphan drug development and patient access community. Dr. Christensen's talk is entitled: "Implementing Rare Disease Registries - Unique Challenges and Proactive Solutions."
Mapi is a leading global organization, offering evaluation and support of therapeutic strategies. With offices worldwide, Mapi provides high quality and efficient operations to help its clients secure product approval and reimbursement while meeting the needs of patients, physicians, regulatory authorities and health care technology purchasers. For more information about Mapi, visit: http://www.mapigroup.com.